Ranibizumab(Lucentis®))
NICE TA 155, TA 274, TA 283 and TA 298
- Traffic LightRed
- BNF11.8.2
- Licensed IndicatorsChoroidal neovascularisation, Macular oedema, Macular degeneration
- ReferenceAPC Dec 13
- Criteria
- ProvisionalNo
Do you want to add this to your CPD record?
Did you find this page helpful?